Substituted norbornylamino derivatives, processes for their preparation, their use as medicaments or diagnostics, and a medicament comprising them

US6825231B2 · kind B2 · utility

Assignee

• Aventis Pharma Deutschland GmbH · DE

Inventors

• Uwe Heinelt · Wiesbaden, DE
• Hans-Jochen Lang · Hofheim, DE
• Heinz-Werner Kleemann · Bischofsheim, DE
• Jan-Robert Schwark · Frankfurt am Main, DE
• Klaus Wirth · Frankfurt am Main, DE
• Hans-Willi Jansen · Niedernhausen, DE

Key dates

• Filing date: Dec 12, 2000
• Grant date: Nov 30, 2004
• Expiry date: Mar 3, 2021

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07C2603/68
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The application discloses substituted norbornylamino derivatives, processes for their preparation, their use as medicaments or diagnostics and a medicament comprising themSubstituted norbornylamino derivatives having exo-configured nitrogen and an endo-fused five-membered ring of the formula I, or having exo-configured nitrogen and an exo-fused five-membered ring of the formula I a in which R1, R2, R3, R4, R5, A, B, S1, and S2 are as defined in the claims, are highly suitable for use as antihypertensive agents, for reducing or preventing ischemically induced damage, for use as medicaments for surgical interventions for the treatment of ischemias of the nervous system, of stroke and cerebral edema, of shock, of impaired respiratory drive, for the treatment of snoring, as laxatives, as agents against ectoparasites, for the prevention of the formation of biliary calculus, as antiatherosclerotics, as agents against late diabetic complications, carcinomatous disorders, fibrotic disorders, endothelial dysfunction, and organ hypertrophies and hyperplasias.They are inhibitors of the cellular sodium/proton antiporter. They have an influence on serum lipoproteins and can therefore be used fo…